Mesenchymal stromal cell quality assessment system

By constructing a mesenchymal stem cell quality assessment system based on single-cell transcriptome analysis and supervised learning model, the problem of lack of unified standards in the existing technology is solved, and accurate quantitative assessment and safety guarantee of mesenchymal stem cell quality is achieved.

JP2024541583AActive Publication Date: 2024-11-08TASLY STEM CELL BIOLOGY LAB TASLY GRP LTD

Patent Information

Application Number
JP2024532159
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-14
Filing Date
2022-12-16
Publication Date
2024-11-08
Estimated Expiration
2042-12-16

AI Technical Summary

Technical Problem

The prior art lacks unified and accurate standards to evaluate the quality of mesenchymal stem cells, and cannot effectively identify the impact of the microenvironment on cell quality, leading to safety risks and application challenges.

Method used

A mesenchymal stem cell quality assessment system based on single-cell transcriptome analysis and functional clustering methods was established. By constructing a supervised learning model, characteristic genes and weight coefficients are determined, cell heterogeneity is quantified, and cell mass is predicted.

Benefits of technology

Accurate and quantitative evaluation of mesenchymal stem cell quality is achieved, cellular heterogeneity caused by the microenvironment is identified, and the consistency and safety of cell mass is ensured.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541583000001_ABST
    Figure 2024541583000001_ABST
Patent Text Reader

Abstract

The present invention provides a stem cell quality evaluation system, which includes a quality scoring module for calculating a stem cell quality score according to the expression level of characteristic genes related to stem cell quality and the weight coefficient of the characteristic genes, a quality evaluation module for evaluating stem cell quality according to the quality score of the stem cell, and a result output module for outputting a stem cell quality result report, and further includes a subpopulation clustering module for obtaining single cell gene expression data and specific quality attributes of stem cells, and a subpopulation identification module for determining a stem cell quality prediction model, characteristic genes related to stem cell quality and the weight coefficient of the characteristic genes according to the single cell gene expression data and specific quality attributes of stem cells. The present invention can achieve the effect of accurately and quantitatively evaluating stem cell quality, and the system can be used to screen high quality stem cells.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [CROSS REFERENCE TO RELATED APPLICATIONS] This application claims priority to Chinese Patent Application No. 202210043060.6, filed on January 14, 2022, the entire contents of which are incorporated herein by reference.

[0002] [Technical field] The present invention relates to the technical field of mesenchymal stromal cells, and to a system for evaluating the quality of mesenchymal stromal cells. [Background technology]

[0003] Mesenchymal stromal cell therapy is expected to fundamentally change the clinical dilemmas of intractable diseases faced by conventional medicine by restoring tissue functions and treating the root causes of degenerative diseases, and is the future direction of medical development.

[0004] Obtaining sufficient mesenchymal stromal cells through appropriate expansion culture is a necessary prerequisite for supporting research and applications of mesenchymal stromal cells. Meanwhile, during the proliferation process, different microenvironments can cause changes in gene expression and heterogeneity in mesenchymal stromal cells of the same origin. Such heterogeneity greatly hinders scientific research on mesenchymal stromal cells and poses a fatal risk to the clinical application of mesenchymal stromal cells. Therefore, testing for heterogeneity during the proliferation process of mesenchymal stromal cells is an important prerequisite for the clinical development of mesenchymal stromal cell therapy.

[0005] Although single-cell RNA sequencing (scRNA-seq) offers the possibility of investigating cell-to-cell heterogeneity and can preliminarily analyze the heterogeneity of cell subpopulations based on gene expression profiles, it cannot clarify the relationship between cell heterogeneity and cell quality, nor can it quantitatively determine mesenchymal stromal cell quality.

[0006] CN113061638A provides a mesenchymal stromal cell evaluation system that performs sterility tests, safety tests, cell activity tests, and cell morphology tests on mesenchymal stromal cells.

[0007] However, the prior art lacks sound and unified norms and standards for mesenchymal stromal cell quality evaluation, cannot accurately show the effects of microenvironment on mesenchymal stromal cells, and cannot solve the safety problems in mesenchymal stromal cell therapy. The mesenchymal stromal cell industry still faces major challenges such as incomplete quality control systems, incomplete mechanism research, and non-standard clinical applications. Summary of the Invention

[0008] In response to the shortcomings of the prior art and practical needs, the present invention provides a mesenchymal stromal cell quality assessment system that establishes an important classification standard for mesenchymal stromal cell quality at the single cell level. Based on single cell transcriptome analysis and cell subpopulation functional clustering method, a single cell gene expression dataset of mesenchymal stromal cells with quality attribute labels was obtained. A mesenchymal stromal cell quality prediction model was constructed using supervised machine learning method, and the feature genes and the weight coefficients of the feature genes related to mesenchymal stromal cell quality were determined. The quality risk due to the heterogeneity of mesenchymal stromal cells was quantitatively determined.

[0009] First, the present invention provides a mesenchymal stromal cell quality evaluation system including an evaluation subsystem, the evaluation subsystem comprising: a quality scoring module for calculating a quality score of the mesenchymal stromal cells based on the expression levels of the characteristic genes related to the mesenchymal stromal cell quality and the weighting coefficients of the characteristic genes; and a quality assessment module for assessing mesenchymal stromal cell quality based on the quality score of the mesenchymal stromal cell.

[0010] Although clinical mesenchymal stromal cells have the same cell biological properties, they will have heterogeneous changes due to the influence of the microenvironment. In order to indicate the heterogeneity of cells, predict the cell state / fate, and further evaluate the quality of mesenchymal stromal cells, the characteristic genes and the weight coefficients of the characteristic genes related to the quality of mesenchymal stromal cells are determined by means of bioinformatics, and the quality of mesenchymal stromal cells is further evaluated based on the expression levels of the characteristic genes and the weight coefficients of the characteristic genes.

[0011] In the present invention, a supervised machine learning model is trained on a single-cell gene expression dataset labeled with quality attributes, and feature genes and weighting coefficients of the feature genes that can accurately characterize the differences between different mesenchymal stromal cells and are related to mesenchymal stromal cell quality are determined. Based on the expression levels of the feature genes and the weighting coefficients of the feature genes of the examined mesenchymal stromal cell samples, a quality score of the mesenchymal stromal cells is calculated to quantitatively evaluate the mesenchymal stromal cell quality.

[0012] Preferably, the quality scoring module includes: (1) a feature gene expression level acquisition unit for obtaining expression levels of feature genes related to mesenchymal stromal cell quality; and (2) a calculation unit for calculating a quality score of mesenchymal stromal cells based on the expression levels of the feature genes and the weighting coefficients of the feature genes, and the calculation function of the quality score of the mesenchymal stromal cells is as follows:

[0013]

number

[0014] Preferably, the method for obtaining the expression level of the characteristic gene includes common gene quantification methods in the art, such as single-cell sequencing, high-throughput sequencing, microarray chip, qPCR, etc. Preferably, the expression level of the characteristic gene is obtained by single-cell sequencing.

[0015] Preferably, the quality assessment module includes: (1) a mesenchymal stromal cell quality risk threshold judgment unit for analyzing the quality score of the dataset by a receiver operating characteristic curve and an area under the curve, where the numerical value of the highest point of the receiver operating characteristic curve is a mesenchymal stromal cell quality risk threshold, and the dataset includes single-cell gene expression data of mesenchymal stromal cells having a known specific quality attribute; and (2) a comparison judgment unit for comparing the quality score of the mesenchymal stromal cell with the mesenchymal stromal cell quality risk threshold, where if the quality score of the mesenchymal stromal cell is≧the mesenchymal stromal cell quality risk threshold, the mesenchymal stromal cell is a quality risk mesenchymal stromal cell, and if the quality score of the mesenchymal stromal cell is<the mesenchymal stromal cell quality risk threshold, the mesenchymal stromal cell is a non-quality risk mesenchymal stromal cell.

[0016] Preferably, the evaluation subsystem further includes a result output module for outputting a result report from the mesenchymal stromal cell quality evaluation module.

[0017] Secondly, in the present invention, a subpopulation clustering module for obtaining single cell gene expression data and specific quality attributes of mesenchymal stromal cells; and a subpopulation identification module for determining and / or optimizing a mesenchymal stromal cell quality prediction model, feature genes associated with mesenchymal stromal cell quality, and weighting coefficients of the feature genes based on single-cell gene expression data and specific quality attributes of the mesenchymal stromal cells.

[0018] Preferably, the subpopulation clustering module includes: (1) a single-cell gene expression data acquisition unit for preprocessing single-cell RNA sequencing data to obtain single-cell gene expression data of mesenchymal stromal cells; (2) a pathway score matrix acquisition unit for performing pathway enrichment analysis on the single-cell gene expression data of mesenchymal stromal cells, calculating pathway scores in each mesenchymal stromal cell for each gene-enriched pathway, and obtaining a score matrix of single-cell pathway enrichment of mesenchymal stromal cells; and (3) a specific quality attribute determination unit for performing standardization, dimensionality reduction, clustering, and visualization processes on the pathway score matrix of single-cell pathway enrichment of mesenchymal stromal cells, and obtaining a clustering result of single-cell subpopulations of mesenchymal stromal cells as a specific quality attribute of mesenchymal stromal cells.

[0019] In the present invention, a pathway score matrix is ​​constructed by combining traditional cell subpopulation clustering, differential gene analysis and pathway enrichment analysis. In the pathway score matrix, each row represents the expression status of a pathway in different mesenchymal stromal cells, each column represents a cell index, and each grid data represents the expression status of a specific pathway in a specific mesenchymal stromal cell. This pathway-based functional clustering method has achieved the effect of quickly revealing the functional differences of mesenchymal stromal cells.

[0020] Preferably, the subpopulation identification module includes: (1) a dataset creation unit for forming single-cell gene expression data of mesenchymal stromal cells labeled with specific quality attributes into a dataset; (2) a dataset division unit for dividing the dataset into a training set and a test set; (3) a model training unit for training a supervised machine learning model by the training set, adjusting parameters of the supervised machine learning model by cross-validation and the test set, and confirming and / or optimizing a mesenchymal stromal cell quality prediction model; and (4) a feature gene output unit for outputting feature genes and weighting coefficients related to mesenchymal stromal cell quality according to the mesenchymal stromal cell quality prediction model.

[0021] In the present invention, the subpopulation identification module of the mesenchymal stromal cell quality evaluation system functions to take single-cell gene expression data of mesenchymal stromal cells labeled with known quality attributes as a dataset, which is randomly divided into a training set and a test set in a certain ratio, and a supervised machine learning model is trained (the feature quantity of the supervised machine learning model is determined by the training set, and the parameters are adjusted by the test set to optimize the supervised machine learning model), and a mesenchymal stromal cell quality prediction model with good accuracy, precision, recall and F1 score is obtained.

[0022] Preferably, the supervised machine learning model includes any one of a perceptron model, a K nearest neighbors model, a naive Bayes model, a decision tree model, a logistic regression, a support vector machine, a random forest, a boosting model, an EM algorithm, or a conditional random field.

[0023] Preferably, the mesenchymal stromal cells include any one or a combination of at least two of adult mesenchymal stromal cells, embryonic mesenchymal stromal cells, induced pluripotent mesenchymal stromal cells, or mesenchymal stromal cells transformed from mature somatic cells and their derived cells.

[0024] Preferably, the mesenchymal stromal cells include any one or a combination of at least two of mesenchymal stromal cells, mesenchymal stromal cells, multipotent stromal cells, multipotent mesenchymal stromal cells, or medicinal signaling cells.

[0025] Preferably, the mesenchymal stromal cells include any one or a combination of at least two of adipose-derived mesenchymal stromal cells, umbilical cord mesenchymal stromal cells, placenta-derived mesenchymal stromal cells, bone marrow mesenchymal stromal cells, dental marrow mesenchymal stromal cells, menstrual blood-derived mesenchymal stromal cells, amniotic epithelial mesenchymal stromal cells, and bronchial basal cells.

[0026] In the present invention, The subpopulation clustering module of the optimization subsystem provides a method for optimizing the mesenchymal stromal cell quality evaluation system, including preprocessing newly obtained single-cell RNA sequencing data to obtain single-cell gene expression data, performing pathway enrichment analysis on the single-cell gene expression data to calculate pathway scores for each mesenchymal stromal cell to obtain a pathway score matrix, and performing standardization, dimensionality reduction, clustering and visualization processing on the pathway score matrix to obtain clustering results as specific quality attributes of mesenchymal stromal cells.

[0027] The subpopulation identification module of the optimization subsystem incorporates single-cell gene expression data of mesenchymal stromal cells labeled with specific quality attributes into the original dataset to create a new dataset, which is divided into a training set and a test set, trains a supervised machine learning model using the training set, adjusts parameters of the supervised machine learning model through cross-validation and testing using the test set, optimizes the mesenchymal stromal cell quality prediction model, and outputs feature genes and weight coefficients related to mesenchymal stromal cell quality.

[0028] The quality scoring module of the evaluation subsystem obtains expression levels of feature genes related to mesenchymal stromal cell quality, and calculates a quality score of the mesenchymal stromal cell based on the expression levels of the feature genes and the weighting coefficients of the feature genes.

[0029] The calculation function of the quality score of the mesenchymal stromal cells is as follows:

number

[0030] The quality assessment module of the assessment subsystem compares a quality score of the mesenchymal stromal cells to a quality risk threshold, and the dataset includes single-cell gene expression data of the mesenchymal stromal cells labeled with known specific quality attributes.

[0031] If the quality score of the mesenchymal stromal cell is greater than or equal to the mesenchymal stromal cell quality risk threshold, the mesenchymal stromal cell is a quality risk mesenchymal stromal cell.

[0032] If the quality score of the mesenchymal stromal cells is < the mesenchymal stromal cell quality risk threshold, the mesenchymal stromal cells are non-quality risk mesenchymal stromal cells.

[0033] Thirdly, in the present invention, obtaining single-cell gene expression data and specific quality attributes of mesenchymal stromal cells to form a dataset divided into a training set and a test set; and A method for constructing a mesenchymal stromal cell quality prediction model is provided, which includes training a supervised machine learning model using a training set, adjusting parameters of the supervised machine learning model through cross-validation and testing using a test set, and determining the mesenchymal stromal cell quality prediction model.

[0034] Preferably, the method for obtaining single cell gene expression data and specific quality attributes of said mesenchymal stromal cells comprises: Obtain single-cell gene expression data of mesenchymal stromal cells by performing single-cell RNA sequencing on mesenchymal stromal cells. Performing pathway enrichment analysis on the single-cell gene expression data of mesenchymal stromal cells and calculating the pathway enrichment score for each mesenchymal stromal cell to obtain a pathway score matrix; and This includes performing bioinformatics analysis on the pathway score matrix to obtain clustering results of mesenchymal stromal cells as specific quality attributes of mesenchymal stromal cells.

[0035] Preferably, the bioinformatics analysis of the pathway score matrix of the mesenchymal stromal cell comprises: This involves performing dimensionality reduction and clustering procedures on the pathway score matrix.

[0036] Preferably, the construction method further includes determining feature genes and weighting coefficients of the feature genes associated with mesenchymal stromal cell quality by a mesenchymal stromal cell quality prediction model.

[0037] Compared with the prior art, the present invention has the following beneficial effects: (1) The mesenchymal stromal cell quality evaluation system of the present invention uses a quality scoring module and a quality evaluation module to accurately and quantitatively evaluate the quality of mesenchymal stromal cells based on the determined mesenchymal stromal cell quality-related characteristic genes and the weighting coefficients of the characteristic genes. The system outputs the mesenchymal stromal cell quality based on the weighted sum of the mesenchymal stromal cell quality-related characteristic genes and the quality risk threshold, and is a regular, complete and unified mesenchymal stromal cell quality evaluation system. (2) The mesenchymal stromal cell quality evaluation system of the present invention uses a subpopulation clustering module and a subpopulation identification module to continuously update a mesenchymal stromal cell quality standard map at the single-cell level based on accumulated single-cell RNA sequencing data of mesenchymal stromal cells. Using this mesenchymal stromal cell quality standard map as a data set, a mesenchymal stromal cell quality prediction model is optimized based on a supervised machine learning model, and the accuracy of the mesenchymal stromal cell quality evaluation results is improved. (3) The mesenchymal stromal cell quality evaluation system of the present invention achieved the effect of accurately and quantitatively indicating the cellular heterogeneity of mesenchymal stromal cells due to the influence of the microenvironment. (4) The mesenchymal stromal cell quality evaluation system of the present invention can be used for screening high-quality mesenchymal stromal cells. [Brief description of the drawings]

[0038] [Figure 1A] FIG. 1A is a growth curve of D1M1-P5. [Figure 1B] FIG. 1B is a growth curve of D1M2-P5. [Figure 1C] FIG. 1C is a cell cycle analysis of D1M1-P5. [Figure 1D] FIG. 1D is a cell cycle analysis of D1M2-P5. [Figure 1E] FIG. 1E shows the apoptotic group of D1M1-P5. [Figure 1F] FIG. 1F shows the apoptotic group of D1M2-P5. [Figure 1G] FIG. 1G shows adipogenic, osteogenic and chondrogenic differentiation of D1M1-P5. [Figure 1H] FIG. 1H shows adipogenic, osteogenic and chondrogenic differentiation of D1M2-P5. [Figure 2A] FIG. 2A shows lung tissues and HE staining results when D1M1-P5, D1M2-P5, or saline was injected into mice (black arrows indicate venous thrombus formation). [Figure 2B]FIG. 2B shows the density of emboli expressed in each 10× field (*p<0.05). [Figure 2C] FIG. 2C shows the results of lung fluorescence in mice injected with D1M1-P5, D1M2-P5, or saline. [Figure 2D] FIG. 2D shows the number of PKH26+ expressing cells in each 10× field. [Figure 3A] FIG. 3A shows the clustering results of D1M1-P5 and D1M2-P5 cell subpopulations (0, 1, 2, 3, 4, and 5 represent different mesenchymal stromal cell subpopulations, respectively). [Figure 3B] FIG. 3B shows the expression of different mesenchymal stromal cell subpopulations for risk genes based on the GO-BP database (C0, C1, C2, C3, C4, and C5 (corresponding to mesenchymal stromal cell subpopulations 0, 1, 2, 3, 4, and 5 in FIG. 3A) represent different mesenchymal stromal cell subpopulations, respectively). [Figure 3C] FIG. 3C shows the expression of different mesenchymal stromal cell subpopulations for risk genes based on the KEGG database (C0, C1, C2, C3, C4, and C5 (corresponding to mesenchymal stromal cell subpopulations 0, 1, 2, 3, 4, and 5 in FIG. 3A ) represent different mesenchymal stromal cell subpopulations, respectively). [Figure 4] FIG. 1 is a schematic diagram of the mechanism of the functional clustering method. [Figure 5A] FIG. 5A shows the functional clustering results of cell subpopulations obtained by the ssGSEA scoring function (A2105C2P5 (i.e., D1M1-P5) were quality risk mesenchymal stromal cells, and A2105C3P5 (i.e., D1M2-P5) were both non-quality risk mesenchymal stromal cells). [Figure 5B] FIG. 5B shows the functional clustering results of cell subpopulations obtained by the AUCell scoring function (A2105C2P5 (i.e., D1M1-P5) were all quality risk mesenchymal stromal cells, and A2105C3P5 (i.e., D1M2-P5) were all non-quality risk mesenchymal stromal cells). [Figure 5C]FIG. 5C shows the functional clustering results of cell subpopulations obtained by the Seurat scoring function (A2105C2P5 (i.e., D1M1-P5) were all quality risk mesenchymal stromal cells, and A2105C3P5 (i.e., D1M2-P5) were all non-quality risk mesenchymal stromal cells). [Figure 6] FIG. 1 is a schematic diagram of cross-culture of mesenchymal stromal cells. [Figure 7A] Figure 7A shows the functional clustering results of cell subpopulations obtained by the ssGSEA scoring function (D1M1-P3, D1M1-P5, and D1M2 / M1-P5 were all quality risk mesenchymal stromal cells, and D1M2-P3, D1M2-P5, and D1M1 / M2-P5 were all non-quality risk mesenchymal stromal cells). [Figure 7B] Figure 7B shows the functional clustering results of cell subpopulations obtained by the AUCell scoring function (D1M1-P3, D1M1-P5, and D1M2 / M1-P5 were all quality risk mesenchymal stromal cells, and D1M2-P3, D1M2-P5, and D1M1 / M2-P5 were all non-quality risk mesenchymal stromal cells). [Figure 7C] Figure 7C shows the functional clustering results of cell subpopulations obtained by the Seurat scoring function (D1M1-P3, D1M1-P5, and D1M2 / M1-P5 were all quality risk mesenchymal stromal cells, and D1M2-P3, D1M2-P5, and D1M1 / M2-P5 were all non-quality risk mesenchymal stromal cells). [Figure 8A] FIG. 8A shows lung tissue and HE staining results when D1M1-P3, D1M2-P3, D1M2 / M1-P5, D1M2 / M1-P5, or saline was injected into mice (black arrows indicate venous thrombus formation). [Figure 8B] FIG. 8B shows the density of emboli expressed in each 10× field (*p<0.05). [Figure 9] FIG. 1 is a schematic diagram of the construction mechanism of the mesenchymal stromal cell quality prediction model. [Figure 10]Figure 1 shows the change curves of cross-validation accuracy with increasing gene quantity in the recursive feature reduction (RFE) process, and the enlarged inflection points of eight different RFE change curves (M1, M2, M3, M4, M5, M6, M7, and M8). [Figure 11] This is the quality score threshold with the highest sensitivity and specificity for classifying mesenchymal stromal cells into quality risk or non-quality risk mesenchymal stromal cells in the four measurement datasets. [Figure 12A] FIG. 12A is a density distribution of mesenchymal stromal cell quality scores for test set 1. [Figure 12B] FIG. 12B is the density distribution of mesenchymal stromal cell quality scores for test set 2. [Figure 12C] FIG. 12C is the density distribution of mesenchymal stromal cell quality scores for test set 3. [Figure 12D] FIG. 12D is the density distribution of mesenchymal stromal cell quality scores for test set 4. [Figure 13A] FIG. 13A is a schematic diagram of the evaluation subsystem 10 of the mesenchymal stromal cell quality evaluation system (110: quality scoring module, 120: quality evaluation module). [Figure 13B] FIG. 13B is a schematic diagram of the quality scoring module 110 (1110: feature gene expression level acquisition unit, 1120: calculation unit). [Figure 13C] FIG. 13C is a schematic diagram of the quality assessment module 120 (1210: quality risk threshold determination unit, 1220: comparison and judgment unit). [Figure 13D] FIG. 13D is a schematic diagram of the optimization subsystem 20 of the mesenchymal stromal cell quality assessment system (210: subpopulation clustering module, 220: subpopulation identification module). [Figure 13E] FIG. 13E is a schematic diagram of the subpopulation clustering module 210 (2110: single-cell gene expression data acquisition unit, 2120: pathway score matrix acquisition unit, 2130: specific quality attribute determination unit). [Figure 13F]FIG. 13F is a schematic diagram of the subpopulation identification module 220 (2210: dataset creation unit, 2220: dataset division unit, 2230: model training unit, 2240: feature gene output unit). [Figure 13G] FIG. 13G is a schematic diagram of the mesenchymal stromal cell quality evaluation system (10: evaluation subsystem, 20: optimization subsystem). [Figure 14] The quality of D1M1 / M2-P5 and D1M2 / M1-P5 is predicted based on the characteristic genes and the weighting coefficients of the characteristic genes determined by the mesenchymal stromal cell quality prediction model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] In order to further explain the technical means and effects of the present invention, the present invention will be further described below in combination with examples and drawings. It is understood that the specific embodiments described herein do not limit the present invention, but are merely for interpreting the present invention. Various modifications and variations to the method and system of the present invention are obvious to those skilled in the art and do not depart from the scope and substantial content of the present invention. Although the present invention has been described in combination with specific preferred embodiments, it should be understood that the present invention should not be unduly limited to these specific embodiments, as per the claims, and various modifications and additions can be made to the embodiments within the scope of the present invention. Of course, various modifications to the embodiments for carrying out the present invention made by those skilled in molecular biology and related fields are all within the scope of protection of the claims.

[0040] For examples in which specific techniques or conditions are not specified, the techniques and conditions described in the literature or product specifications are followed. Reagents or equipment for which the manufacturer is not specified are all genuine products that can be purchased through official channels.

[0041] definition As used above and below, "mesenchymal stromal cells" refers to a type of relatively undifferentiated cell with differentiation potential, capable of actively dividing and cycling, and providing the appropriate stimuli for mature differentiated and functional cell lines. The properties defined for said mesenchymal stromal cells include (a) that the mesenchymal stromal cells themselves are not terminally differentiated, (b) that they can divide indefinitely throughout the life of an animal, (c) that they are a type of mesenchymal stromal cell, not a mixture of multiple types of mesenchymal stromal cells and / or somatic cells, with outcomes characterized by consistent cell markers, and (d) that when mesenchymal stromal cells divide, each daughter cell can either remain as a mesenchymal stromal cell or undergo a process that irreversibly induces terminal differentiation.

[0042] As described above and below, "multipotent mesenchymal stromal cells" or "mesenchymal stromal cells" are multipotent mesenchymal stromal cells that can differentiate into multiple cell types. Multipotent mesenchymal stromal cells have been shown to differentiate in vitro or in vivo into cell types including osteoblasts, chondrocytes, muscle cells, and adipocytes. Mesenchyme is an embryonic connective tissue derived from the mesoderm that differentiates into hematopoietic and connective tissues, although multipotent mesenchymal stromal cells do not differentiate into hematopoietic cells.

[0043] As mentioned above or below, "mesenchymal stromal cell quality" refers to any one of the above-mentioned relevant factors of mesenchymal stromal cell safety, in which mesenchymal stromal cells are heterogeneous due to the influence of the microenvironment, and such heterogeneity may lead to quality risks. Clinical grade mesenchymal stromal cells are not a mixture of multiple types of mesenchymal stromal cells and / or mesenchymal stromal cells and somatic cells, but contain one type of mesenchymal stromal cells, and require rigorous third-party testing and laboratory testing closely related to the safety, efficacy and consistency of mesenchymal stromal cells, including cell viability, biological function, tumorigenicity, embolicity, immunogenicity, microorganism, mycoplasma, endotoxin testing, etc. In order to avoid acute or subacute severe adverse reactions such as fever, allergy, bacteremia, etc. during or after transplantation, qualified mesenchymal stromal cells should undergo release testing before their transplantation, and further undergo compatibility testing against microorganisms, mycoplasma and endotoxins.

[0044] As described above or below, "characteristic genes related to mesenchymal stromal cell quality" refers to genes that define mesenchymal stromal cell quality categories. High expression of these genes increases or decreases the quality risk of mesenchymal stromal cells.

[0045] As stated above and below, "expression level" refers to the expression level of a gene.

[0046] As described above or below, the "mesenchymal stromal cell quality score" refers to a score calculated by the following calculation function based on the expression levels of the characteristic genes and the weighting coefficients of each characteristic gene determined by the mesenchymal stromal cell quality prediction model.

[0047]

number

[0048] As described above or below, the "gene expression level" refers to the expression level of a specific gene in a cell measured by a general method in the field of molecular biology. For example, it includes the value of the hybridization level measured as the fluorescence intensity between the probe nucleic acid immobilized on the surface of a DNA chip plate (measurement data) and the estimated value of the gene expression level obtained based on the value.

[0049] As described above or below, a "specific quality attribute" refers to the clustering result of a subpopulation of a single mesenchymal stromal cell determined by a subpopulation clustering method, i.e., "quality risk mesenchymal stromal cells" or "non-quality risk mesenchymal stromal cells."

[0050] As described above or below, a "pathway score matrix" is a matrix of pathway identities in columns and cell indices in rows, with data in each grid representing the expression status of a particular pathway in a particular mesenchymal stromal cell. Data analysis methods (including supervised and unsupervised data analysis, as well as bioinformatics methods) are presented in Brazma and ViIo J, 2000, FEBS Lett 480(1):17-24.

[0051] In the following examples, an example of the risk of mesenchymal stromal cell-induced embolism closely related to mesenchymal stromal cell quality is described, but those skilled in the art can understand that the tumorigenicity and immunogenicity of mesenchymal stromal cells can be identified by substantially the same method and means according to the present invention. For example, the characteristic gene associated with tumorigenicity may be c-myc, and the characteristic gene associated with immunogenicity may be dnam-1, mcp-1.

[0052] The risk of mesenchymal stromal cell-induced embolism is the most typical risk of mesenchymal stromal cell application and one of the most important factors affecting mesenchymal stromal cell quality. In the past 20 years, many clinical cases have been reported in which embolic complications occurred after mesenchymal stromal cell therapy (Woodard, JP et al. Pulmonary cytolytic thrombi: a newly recognized complication of stem cell transplantation. Bone Marrow Transpl 25, 293-300 (2000).; Tatsumi, K. et al. Tissue factor triggers procoagulation in transplanted multipotent mesenchymal stromal cells leading to thromboembolism. Biochem Biophys Res Commun 431, 203-209 (2013).). From this, it can be understood that a person skilled in the art can use the evaluation of the risk to evaluate the quality of mesenchymal stromal cells. EXAMPLES

[0053] Example 1: Obtaining and culturing multipotent mesenchymal stromal cells 1. Obtaining Multipotent Mesenchymal Stromal Cells (1) Collection of adipose tissue Adipose tissue was collected from donors (negative for AIDS virus, hepatitis B virus, hepatitis C virus, human T-cell virus, EB virus, cytomegalovirus, and Treponema pallidum) in a sterile environment. Adipose tissue (50-150 mL) was placed in a sealed container to which 100 mL of tissue preservation solution (purchased from TIAN JIN HAO YANG BIOLOGICAL MANUFACTURE Co., Ltd.) had been added beforehand, and was prepared by storing at 2-8°C. 30 mL of tissue preservation fluid was pipetted and tested for bacterial, endotoxin and mycoplasma contamination, and the tissue was then used for isolation of pluripotent mesenchymal stromal cells.

[0054] (2) Isolation of multipotent mesenchymal stromal cells The same volume of Dulbecco's phosphate buffered saline (dPBS) was added to the adipose tissue, the container containing the tissue was sealed, vigorously shaken for 20 seconds, and left to stand for 5 minutes. After the adipose tissue and dPBS were completely separated, the lower layer liquid was discarded, and the adipose tissue was repeatedly washed with dPBS until the lower layer liquid was no longer red. A 20 mL aliquot of the washed adipose tissue was placed in a 50 mL centrifuge tube, and the same volume of dPBS was added and centrifuged at 400 g for 5 minutes. The solution was separated into an upper oily layer, a middle adipose tissue layer, and a lower layer of dPBS and blood cell precipitate. The upper oily layer, lower dPBS and blood cell precipitate were removed. Two volumes of 1 mg / mL type I collagenase (purchased from Gibco, catalog number: 17100-017) were added to the adipose tissue. The container with the tissue was sealed and transferred to a thermostatic air shaker preheated to 37° C. The tissue was digested with collagenase at 120 rpm / min for 1 hour.

[0055] (3) Collection of multipotent mesenchymal stromal cells The digested tissue was centrifuged at 500g for 8 minutes at room temperature. After centrifugation, the tissue was separated into an upper oily layer, a middle adipose tissue layer, a lower digestion solution, and a bottom cell precipitate. The upper oily layer, the middle adipose tissue layer, and the bottom digestion solution were discarded. The bottom cell precipitate was resuspended in dPBS, filtered through a 100 μm filter, and centrifuged at 500g for 5 minutes in a 50 mL centrifuge tube. The supernatant was removed to obtain a cell precipitate containing primary human adipose-derived stromal cells (hADSCs). The complete medium was added to the centrifuge tube in the same volume as the adipose tissue, and mixed evenly to thoroughly release the digested cells, obtaining a cell suspension containing primary human adipose-derived stromal cells.

[0056] 2. Culturing Multipotent Mesenchymal Stromal Cells Primary human adipose-derived stromal cells were cultured in different media M1 (αMEM + 10% FBS, αMEM purchased from Thermo Fisher, FBS purchased from ExCell Bio) or M2 (DMEM / F-12 + 5% Helios UltraGRO-Advanced, DMEM / F-12 purchased from Thermo Fisher, Helios UltraGRO-Advanced purchased from Helios BioScience), and the specific steps were as follows:

[0057] (1) Primary culture The cell pellet was resuspended in M1 medium / M2 medium, and 1.5 mL of the cell suspension was inoculated into a T75 cell culture flask to which 8.5 mL of M1 medium / M2 medium had previously been added. After labeling the T75 cell culture flask, it was transferred to a cell culture incubator and cultured at 37°C and 5% CO2. After 24 hours, most of the primary human adipose-derived stromal cells had attached to the wall. The supernatant was removed and 10 mL of M1 medium / M2 medium was added. The medium was then changed every 3 days. Microscopic observation showed that in addition to primary human adipose-derived stromal cells, the obtained primary cells contained many heterocytic cells and matrix components, and had the typical long spindle shape of human adipose-derived stromal cells.

[0058] (2) Subculture When the primary human adipose-derived stromal cells were 50%-70% confluent, the medium was removed and the cells were washed once with 10 mL of dPBS. TM 1.5 mL of -Express (1x) (purchased from Gibco, catalog number: 12604-021) was added and digested for 1-2 minutes. After some cells became round and fell off, the culture flask was gently tapped and 4.5 mL of dPBS was added to terminate the digestion. The liquid was collected in a 50 mL centrifuge tube. After washing once with 10 mL of dPBS, it was centrifuged at 400 g for 5 min. The upper layer was a mixture of the digestion solution and dPBS, and the lower layer was a white precipitate, i.e., a precipitate containing primary human adipose-derived stromal cells. The supernatant was removed, and the white precipitates in the multiple centrifuge tubes were collected in one centrifuge tube and resuspended in M1 medium / M2 medium until the volume reached 30 mL. The cell suspension was then mixed uniformly and used for cell counting. The counted cells were resuspended in M1 medium / M2 medium and counted at 5000-6000 cells / cm. 2 The cells were passaged at a density of 100 x 100 μg / ml. The cell culture flask was labeled with information such as cell batch, passage number, and culture time, and placed in a cell culture incubator. When the cells reached approximately 90% confluence, they were passaged again. The 3rd and 5th passage pluripotent mesenchymal stromal cells were collected and stored under refrigeration, and were named D1M1-P3 (representing pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells derived from donor 1 in M1 medium up to the 3rd passage), D1M2-P3 (representing pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells of donor 1 in M2 medium up to the 3rd passage), D1M1-P5 (representing pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells of donor 1 in M1 medium up to the 5th passage), and D1M2-P5 (representing pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells of donor 1 in M2 medium up to the 5th passage).

[0059] Example 2 Quality control of multipotent mesenchymal stromal cells In this example, the refrigerated samples were thawed quickly in a 37°C water bath with continuous stirring, and the multipotent mesenchymal stromal cells were resuspended in pre-warmed dPBS, centrifuged at 400g for 5 min, and washed twice with dPBS. Finally, the multipotent mesenchymal stromal cells (D1M1-P3, D1M2-P3, D1M1-P5, D1M2-P5) were counted and used for quality control. 1.Microbiological safety testing (1) Sterility test According to the Chinese Pharmacopoeia 2020 Edition (Part 4) General Provision 1101 Sterility Test Method, the steps are briefly described as follows: After wetting the filter membrane of a disposable triple bacterial collector (purchased from Zhejiang Tailin Bioengineering Co., Ltd.) with 100 mL of 0.9% saline (purchased from SJZ No.4 Pharmaceutical), each hADSC sample was introduced into the bacterial collector for filtration. After filtration, the filter membrane was washed twice with 300 mL of 0.9% saline. Two different media were used: thioglycollate broth for anaerobic and aerobic bacteria testing, and trypticase soy broth (TSB), a soybean-casein-digest medium, for anaerobic and aerobic bacteria testing. Two of the triple bacterial collectors containing samples were each filled with 100 mL of thioglycollate broth and the other with 100 mL of TSB. One mL of 0.9% saline in place of the sample served as a negative control, and Staphylococcus aureus (bacterial loading less than 100 CFU) served as a positive control. After inoculation, the media were gently shaken and incubated under the conditions recommended by the sterility test as follows: the liquid thioglycollate medium was placed at 30-35°C, and the remaining media were placed at 20-25°C and incubated for 14 days. After a total of 14 days of incubation, bacterial growth was observed and recorded on each working day during the incubation period.

[0060] (2) Mycoplasma test According to the Chinese Pharmacopoeia 2020 Edition (Part 4) General Provision 3301 Mycoplasma Testing Method, the steps are briefly described as follows: Mycoplasma broth medium, arginine-containing mycoplasma broth medium, mycoplasma semi-solid medium, and arginine-containing mycoplasma semi-solid medium were prepared according to conventional recipes and sterilized. Next, 800,000 units of sodium penicillin for injection (purchased from Jiangxi Dongfeng Pharmaceutical Co., Ltd.) was redissolved in 1 mL of 0.9% saline to prepare the medium. For every 800 mL of sterilized medium, 200 mL of fetal bovine serum and 800,000 units of sodium penicillin for injection were added, mixed uniformly, and stored at 2-8°C. Four Mycoplasma broth media (10 mL / bottle), four Arginine-containing Mycoplasma broth media (10 mL / bottle), two Mycoplasma semi-liquid media (10 mL / bottle), and two Arginine-containing Mycoplasma semi-liquid media (10 mL / bottle) were inoculated with 1.0 mL of cell sample and cultured at 36 ± 1°C for 21 days, with observations made once every 3 days. On the seventh day after inoculation, two bottles of mycoplasma broth medium inoculated with the cell sample and two bottles of arginine-containing mycoplasma broth medium inoculated with the cell sample were taken and subcultured. With an inoculation volume of 1 mL, each bottle of mycoplasma broth medium was subcultured into two arginine-containing mycoplasma semi-solid medium and two mycoplasma broth medium, respectively, and each bottle of arginine-containing mycoplasma broth medium was subcultured into two arginine-containing mycoplasma semi-solid medium and two arginine-containing mycoplasma broth medium, respectively, and cultured at 36°C ± 1°C for 21 days, and observed once every 3 to 5 days.

[0061] (3) Endotoxin test According to the Chinese Pharmacopoeia 2020 Edition (Part 4) General Provision 1143 Bacterial Endotoxin Testing Method, the steps are briefly described as follows: The secondary standard (purchased from Zhanjiang A&C Biological Ltd.) was reconstituted with 1 mL of endotoxin test water (purchased from Zhanjiang A&C Biological Ltd.), mixed uniformly on a vortex shaker for 15 minutes, and then gradient dilutions were performed. For each dilution, the solution was mixed on a vortex shaker for 30 seconds, and finally diluted to 4λ and 2λ endotoxin standard solutions. The cell suspension was diluted with endotoxin test water, and each dilution was mixed for 30 seconds on a vortex shaker. The diluted solution was used as the test sample. The dilution rate was less than or equal to the maximum valid dilution factor (MVD), which was calculated by the formula MVD = C × L / λ, where L is the limit value of endotoxin in the sample, C is the concentration of the test sample, and λ is the sensitivity of the Limulus reagent. One test sample was added to the 4λ endotoxin standard solution in a 1:1 volume ratio to serve as the endotoxin positive control. Eight Limulus reagents (purchased from Zhanjiang A&C Biological Ltd.) were reconstituted with 0.1 mL of endotoxin test water. Two Limulus reagents were added with 0.1 mL of endotoxin positive control solution to serve as parallel cell positive control (PPC). Two Limulus reagents were added with 0.1 mL of 2λ endotoxin standard solution to serve as parallel positive control (PC). Two Limulus reagents were added with 0.1 mL of endotoxin test water to serve as parallel negative control (NC). Two Limulus reagents were added with 0.1 mL of cell solution with a dilution rate below MVD to serve as parallel cell test. The reaction tube was placed in a pre-heated endotoxin gel tester and a 60 minute countdown was started. One minute before the 60 minute countdown ended, the reaction tube was removed and the results were observed and recorded. As shown in Table 1, after 14 days, there was no bacterial growth in the collectors containing the mesenchymal stromal cell samples, and the sterility test results of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were passed. The mycoplasma test results of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were negative, and the test results were passed. The endotoxin test results of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were negative, and the test results were passed.

[0062] [Table 1]

[0063] 2. Phenotype analysis The expression of multipotent mesenchymal stromal cell-specific surface markers CD73, CD90, CD105, CD11b, CD19, CD34, CD45 and HLA-DR in hADSC samples was analyzed by flow cytometry (Reference: M. Dominici et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) Vol. 8, No. 4, 315-317). The steps were as follows:

[0064] hADSC samples at passage 3 or 5 were TM Tryptophan-Express (1x) was used to digest the cells at 37°C for 2-3 minutes. When the cells became round and fell off, TM The digestion was terminated by adding PBS (1x) in a volume three times larger than that of -Express (1x). The cell suspension was transferred to a 50 mL centrifuge tube with a pipette and centrifuged at 300 g for 5 min. The cells were washed twice with PBS (1x) to obtain a viable cell density of (0.5–1) x 10 7 The cells were resuspended to a concentration of 10 cells / mL.

[0065] 100 μL of cell suspension was pipetted into the flow tube and incubated with 5 μL of pre-labeled antibodies (FITC-labeled anti-human CD34, FITC-labeled anti-human CD45, FITC-labeled anti-human CD11b, FITC-labeled anti-human HLA-DR, FITC-labeled anti-human CD73, FITC-labeled anti-human CD90, APC-labeled anti-human CD19, and PE-labeled anti-CD105) at room temperature in the dark for 15 min. As controls, FITC-labeled mouse IgG1, APC-labeled mouse IgG1, and PE-labeled mouse IgG1 were added. The antibodies used were purchased from Biolegend.

[0066] Two milliliters of sheath fluid was added to each flow tube, vortexed, and centrifuged at 300 g for 5 minutes, and the supernatant was removed. The cells were resuspended in 300 μL of 1% paraformaldehyde in PBS (1×) and analyzed by flow cytometry.

[0067] As a result, as shown in Table 2, the expression rates of the positive markers CD73, CD90, and CD105 on the surface of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were more than 95%, and the expression rates of the negative markers CD11b, CD19, CD34, CD45, and HLA-DR on the surface of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 were less than 2%.

[0068] [Table 2]

[0069] 3. Cellular activity test (1) Cell viability analysis The cell suspension was diluted with 0.9% saline and thoroughly mixed with 0.4% trypan blue staining solution at a volume ratio of 9:1. 10 μL of the mixture was pipetted into the counting chamber of the counting plate and observed under a 10x objective lens. The total number of live cells and the total number of dead cells in the four grids were recorded, and the cell viability was calculated according to the following formula: Cell viability (%) = total number of live cells / (total number of live cells + total number of dead cells) x 100% The cell viability of D1M1-P3, D1M2-P3, D1M1-P5, and D1M2-P5 was all above 80%.

[0070] (2) Cell proliferation kinetics When the hADSC samples at passage 5 were 80%–90% confluent, TM The cells were digested with -Express (1x). The cell density was adjusted to 3.2x10 5 pieces / mL, 1.6×10 5 pieces / mL, 0.8×10 5 pieces / mL, 0.4×10 5 pieces / mL, 0.2×10 5 pieces / mL, 0.1×10 5 The cells were adjusted to cells / mL and inoculated into a 96-well microplate at 100 μL / well. 100 μL of complete medium was added to the control wells, and six duplicate wells were set up for each group. After culturing for 4 hours at 37°C and 5% CO2, the medium in each well was discarded, and 110 μL / well of CCK8 solution (DMEM / F12 medium (without phenol red):CCK8 (v / v) = 100:10) was added to each well, followed by incubation for 2 hours at 37°C and 5% CO2. The optical density (OD450) at a wavelength of 450 nm was measured using a multi-function microplate reader. The average OD450 of the control wells was normalized to obtain ΔOD450 values ​​for wells with different cell densities. Curve fitting was performed by linear regression using ΔOD450 as the horizontal axis and cell number as the vertical axis. In a parallel experiment, hADSC samples at passage 5 were cultured at 1 × 10 4Cells were plated at a density of 100 cells / well into 96-well microplates. 100 μL of complete medium was added to control wells. Eight plates were prepared with six replicate wells for each group. The cells were counted every day until day 8. The medium in each well was discarded, and 110 μL / well of CCK8 solution (DMEM / F12 medium (without phenol red):CCK8 (v / v)=100:10) was added, followed by incubation at 37°C and 5% CO2 for 2 hours. OD450 was measured using a multi-function microplate reader. The average OD450 of the control wells was normalized to obtain the delta OD450 value of the well. The cell number of each well was calculated based on the curve by linear regression. A growth curve was constructed from the average values, and the population doubling time was calculated from the growth curve. Figures 1A and 1B show the proliferation curves of D1M1-P5 and D1M2-P5, respectively, in which hADSCs entered the logarithmic proliferation phase after 3 days of culture, entered the stationary phase after 6 days, and began to decline in proliferation ability after 7 days. The population doubling time of D1M1-P5 was 37.5 h, and that of D1M2-P5 was 21.9 h.

[0071] (3) Cell cycle analysis hADSC samples at passage 3 or 5 were TM The cells were digested with 1×-Express (1×) at 37°C for 2–3 min, centrifuged at 1000 rpm for 3–5 min, and the supernatant was carefully discarded. The cell mass was washed twice with 1 mL of pre-chilled PBS (1×) to obtain a cell mass with a density of 1×10 6 The mixture was resuspended to cells / mL. 1 mL of the cell suspension was added drop by drop to 4 mL of pre-chilled 95% ethanol solution while vortexing at low speed (operated on ice). After the cells were mixed uniformly, they were fixed at 4°C for more than 2 hours. Next, the cells were precipitated by centrifugation at 1000 rpm for 3 to 5 minutes. The cells were washed twice with 5 mL of pre-chilled PBS (1x), and the bottom of the centrifuge tube was gently tapped to disperse the cells appropriately and avoid cell aggregation. According to Table 3, a cell cycle and apoptosis detection kit (purchased from Beijing 4A Biotech Co., Ltd.) was used to prepare propidium iodide solution according to the number of samples to be tested. Then, 0.4 mL of propidium iodide solution was added to the cell sample, the cell pellet was slowly resuspended, and incubated at 37°C in the dark for 30 minutes. After washing twice with PBS (1x), the cells were resuspended in PBS (1x) and the cell cycle measurement using flow cytometry was completed within 24 hours.

[0072] [Table 3]

[0073] As shown in the cell cycle analysis results in Figures 1C and 1D, the percentages of D1M1-P5 in the G1, S and G2 phases were 85.69%, 12.56% and 1.75%, respectively, and the percentages of D1M2-P5 in the G1, S and G2 phases were 89.07%, 6.42% and 4.51%, respectively.

[0074] (4) Apoptosis test Tryple 5th passage hADSC samples TM The cells were digested with 1x Binding Buffer (purchased from Beijing 4A Biotech Co., Ltd.) for 2-3 minutes at 37°C and centrifuged at 1000 rpm for 3-5 minutes. The supernatant was carefully discarded. The cell pellets were resuspended in 0.8 mL of 1x Binding Buffer (purchased from Beijing 4A Biotech Co., Ltd.). Density is (2~5)×10 5 200 μL of hADSC samples at 100 μg / mL were added to each flow tube and incubated with 5 μL of Annexin-V-FITC for 10 min in the dark. After centrifugation, cells were resuspended in 200 μL of binding buffer and then incubated with 5 μL of propidium iodide before flow cytometry analysis. As a result, as shown in Figures 1E and 1F, in D1M1-P5, the cell viability was 92.0% and the apoptosis rate was 5.75%, and in D1M2-P5, the cell viability was 91.4% and the apoptosis rate was 0.52%.

[0075] 4. Biological activity analysis (1) Adipogenic differentiation Before the experiment, solutions A and B were prepared according to the instructions for the OriCell kit (purchased from Cyagen Biosciences Inc., catalog number: HUXMD-90031) used for adipogenic differentiation of human adipose-derived mesenchymal stromal cells, and then the following steps were performed. 2 x 10 cells 4 cell / cm 2 The cells were seeded at a density of 100× in 6-well plates, 2 mL of complete medium was added to each well, and the cells were cultured at 37°C and 5% CO2 until they reached 100% confluence. The culture supernatant was discarded. The cells were incubated in 2 mL of solution A for 3 days, then replaced with 2 mL of solution B and incubated for 24 hours. After repeating this three times, the cells were subsequently cultured in solution B for 4 to 7 days until the lipid droplets became sufficiently large and round. The cells were washed, fixed with 4% paraformaldehyde solution, and stained with 0.5% Oil Red O for 20 min at room temperature. After washing three times with PBS (1×), images were taken with an inverted phase contrast microscope.

[0076] (2) Osteogenic differentiation Before the experiment, osteogenic medium was prepared according to the instructions for the OriCell kit (purchased from Cyagen Biosciences Inc., catalog number: HUXMD-90021) used for osteogenic differentiation of human adipose-derived mesenchymal stromal cells, and then the following steps were performed. 2 x 10 cells 4 cell / cm 2 The cells were seeded into a 6-well plate at a density of 1000×, ... The culture medium supernatant was discarded. The cells were incubated in 2 mL of osteogenic medium, which was replaced once every 3 days, for 2 to 4 weeks, at which time significant calcium deposition was observed under an inverted microscope. The cells were washed, fixed with 4% paraformaldehyde solution, and stained with Alizarin Red S for 5 min at room temperature. After washing three times with PBS (1×), images were taken with an inverted phase contrast microscope.

[0077] (3) Chondrogenic differentiation Before the experiment, chondrogenic medium was prepared according to the instructions for the OriCell kit (purchased from Cyagen Biosciences Inc., catalog number: HUXMD-90041) used for chondrogenic differentiation of human adipose-derived mesenchymal stromal cells, and then the following steps were performed. 0.1% gelatin was added to a 6-well plate, shaken gently to cover the bottom of the wells, allowed to stand for 30 minutes, the gelatin discarded, and the plate allowed to dry. 1 × 10 cells of passage 5 4 cell / cm 2 The cells were seeded at a density of 100 μg / well onto a 6-well plate coated with 0.1% gelatin, 2 mL of complete medium was added to each well, and the cells were cultured at 37°C and 5% CO2 conditions until the cells reached 80-90% confluence. The culture supernatant was discarded. Cells were induced in 2 mL of fresh chondrogenic medium (containing 20 μL of TGF-β3) and the chondrogenic medium was replaced once every 2-3 days for 2 weeks. Control wells were continuously cultured with complete medium. The cells were washed, fixed with 4% paraformaldehyde solution, and stained with Alcian blue for 30 min at room temperature. After washing three times with PBS (1×), images were taken with an inverted phase contrast microscope. As shown in Figure 1G and Figure 1H, which shows the differentiation status of multipotent mesenchymal stromal cells in an in vitro environment, multipotent mesenchymal stromal cells were induced to undergo adipogenic, osteogenic and chondrogenic differentiation, and as a result, it was shown that D1M1-P5 and D1M2-P5 were successfully induced into adipogenic cells, osteoblasts and chondroblasts, respectively. These results indicate that both passage 3 and passage 5 mesenchymal stromal cells cultured in different media are multipotent mesenchymal stromal cells and meet the recognized standards for mesenchymal stromal cell quality control.

[0078] Example 3 Animals treated with pluripotent mesenchymal stromal cells 1. Intravital Injection of Multipotent Mesenchymal Stromal Cells Male NCG mice aged 6 to 8 weeks (purchased from Gempharmatech Co., Ltd.) were randomly divided into groups. After fixing the mice, the injection site was disinfected. The fifth-passage hADSC samples (D1M1-P5 or D1M2-P5) that had passed quality control were resuspended in 0.9% saline and diluted to 1 × 10 6 The cells were slowly injected into each mouse via the tail vein at a dose of 100 cells / mouse. The control group was injected with 0.9% saline. After injection, the survival rate of the mice was recorded within 3 minutes. All 6 mice injected with D1M1-P5 died within 3 minutes, whereas all 6 mice injected with D1M2-P5 and 6 mice injected with 0.9% saline were observed to be alive within 3 minutes. After the observation was completed, the mice were anesthetized with Avertin and euthanized by cutting the abdominal aorta.

[0079] 2. Immunohistochemistry (1) Gathering materials The skin and muscles of the mouse were cut, the thoracic cavity was exposed, the right ventricle was punctured with a syringe, and 5 mL of 0.9% saline was slowly perfused throughout the body until the outflowing liquid was relatively clear with no obvious blood color. The lungs of the mouse were promptly harvested. Visual pathological observation was performed, and the tissues were fixed in 10% formalin solution for 2 days.

[0080] (2) Hematoxylin-eosin staining According to common laboratory procedures, the obtained lung tissues were dehydrated in gradient ethanol, embedded in paraffin, sectioned, stained with hematoxylin-eosin (HE), and finally observed under a light microscope. Figure 2A shows the pathological results of lung tissue after injection of D1M1-P5, D1M2-P5 or saline into mice, and compared with the control group, mice injected with D1M1-P5 showed pulmonary congestion and severe pulmonary embolism, whereas D1M2-P5 did not show any adverse reactions. Figure 2B also shows that mice injected with D1M1-P5 had a large number of venous thrombi in the lungs, and the density of the embolism was significantly higher than that of the D1M2-P5 group and the control group. Furthermore, fluorescent PKH26-labeled D1M1-P5 or D1M2-P5 was injected into a mouse model, and the number of PKH26-positive cells in the lungs was counted. As a result, as shown in Figures 2C and 2D, consistent with the immunohistochemical results, a large amount of PKH26 was detected in the lungs of mice that had developed thrombi. + D1M1-P5 were observed, indicating that mesenchymal stromal cells grown under different culture conditions underwent different biological processes or formed different lineages.

[0081] Example 4 Single-cell RNA sequencing To identify the heterogeneity of mesenchymal stromal cells in different media, we examined the gene expression profile of mesenchymal stromal cells at the single-cell level by performing single-cell RNA sequencing. The steps were as follows: 1. Preparation of Single-cell Suspension The fifth passage hADSC samples (D1M1-P5 and D1M2-P5) were diluted with sample buffer to a cell suspension with a concentration of <1000 cells / μL. 1 μL of Calcein AM dye and 1 μL of Draq7 dye were added to 200 μL of the cell suspension to perform cell staining. Filter the stained cell suspension through a 40 µm filter and eluate with BD Rhapsody TMThe cells were placed in a scanner to measure cell density and cell viability. Dilutions of the cell suspension were prepared based on the stock cell and buffer volumes obtained from the sample calculator function of the scanner.

[0082] 2. Single Cell Sorting The diluted cell suspension was loaded onto a Cartridge workflow equipped with 200,000 microwells (Cartridge Kit, purchased from BD Biosciences, catalog number: 633733), and the cell loading amount and doublet rate were analyzed to evaluate the effectiveness of single cell separation. After washing to remove unloaded cells, BD Rhapsody beads were loaded into Cartridge workflow and analyzed for bead and cell loading and doublet percentage to assess the number of beads bound within single cell wells. After washing to remove excess beads, the cell lysis solution was added to Cartridge workflow to lyse the cells. The mRNA contained in each cell was captured by the probe via the polyA / polyT on the surface of the BD Rhapsody beads, which have the same cell label (CL) and various molecular barcodes (UMI). The BD Rhapsody beads were collected from the Cartridge workflow into a centrifuge tube.

[0083] 3. Single-cell cDNA Synthesis and Library Construction Single-cell first-strand cDNA was reverse-synthesized and libraries were constructed using the Cartridge kit (purchased from BD Bioscience, Catalog No. 633731) and the Whole Transcriptome Analysis (WTA) Amplification Kit (purchased from BD Bioscience, Catalog No. 633801). The following procedures were performed according to the kit's instruction manual, which are briefly described below. The collected beads were washed, and the reverse transcription reagent (Table 4) was added and mixed with the beads, followed by incubation at 37° C. for 45 minutes.

[0084] [Table 4]

[0085] Exonuclease was added, incubated at 37°C for 30 minutes, and then incubated at 80°C for 20 minutes to remove probes that were not connected to mRNA on the bead surface. Random primer mix (Table 5) was added and incubated at 95°C for 5 min, 37°C at 1200 rpm for 5 min, 25°C at 1200 rpm for 15 min; primer extension mix (Table 6) was added and incubated at 25°C at 1200 rpm for 10 min, 37°C at 1200 rpm for 15 min, 45°C at 1200 rpm for 10 min, 55°C at 1200 rpm for 10 min, and the extended first strand cDNA was eluted with bead-free eluent.

[0086] [Table 5] [Table 6]

[0087] The random primer extension (RPE) products were added to a PCR amplification mixture (Table 7) containing universal and specific primers, and amplification was carried out using the process in Table 8, followed by enrichment and purification of the amplified products.

[0088] [Table 7] [Table 8]

[0089] The amplified products were used as templates for PCR using the Whole Transcriptome Index PCR Amplification Mix (Table 9), and amplification was performed according to the process in Table 10 (if the molar concentration of the amplified product is 1-2 nM, amplification was performed for 9 cycles; if the molar concentration of the amplified product is >2 nM, amplification was performed for 8 cycles). The new amplified products were enriched and purified to obtain single-cell sequencing libraries.

[0090] [Table 9] [Table 10]

[0091] 4. Single-cell Sequencing Library Quality The concentration of the single-cell sequencing library was measured by a Qubit instrument, and the fragment length of the single-cell sequencing library was measured by an Agilent 2100 bioanalyzer, which showed that the library concentration was 0.1-100 ng / μL and the fragment length of the library was 460-550 bp.

[0092] 5. Single-cell Sequencing The molar concentration of the single-cell sequencing library calculated based on the library concentration and fragment length was 1 to 100 nM. After dilution to a standard molar concentration of 0.2 to 2 nM, the sequencing control library PhiX, which has the same molar concentration as the single-cell sequencing library, was mixed in a ratio of single-cell sequencing library:sequencing control library = 1:(0.05 to 0.5) and sequencing was performed.

[0093] 6. Sequencing Data Quality Sequencing data were analyzed by BD cwl-runner 3.1 to assess the quality of the raw sequencing data. 5095 D1M1-P5 and 3249 D1M2-P5 were sequenced with an average sequencing depth of 50K / cell.

[0094] Example 5. Clustering of subpopulations Raw sequencing data were converted to FASTQ format and the quality of the sequencing data was analyzed. The BD Rhapsody analysis pipeline v1.9.1 (BD Biosciences) was used for cell barcode identification, read alignment, and UMI quantification using default parameters. 1. Data Preprocessing Quality control: sequences with read1 length < 60, read2 length < 42, read1 and read2 base quality < 20, and sequences with read1 single nucleotide frequency (SNF) ≥ 0.55 or read2 SNF ≥ 0.80 were filtered out. Alignment and annotation: Quality-controlled valid reads were aligned to the human reference genome GRCh38, and the alignment results were annotated. Gene Expression Matrix: The expressed read counts for each gene in all samples were merged (collapsed) and adjusted to molecular barcode (UMI) counts by recursive permutation error correction (RSEC). Putative cells were discriminated from background noise by second derivative analysis of all RSEC-adjusted UMI counts. The resulting output was a gene expression matrix with gene identities as columns and cell indices as rows.

[0095] 2. Cell Filtering The RSEC-adjusted UMI count matrix was imported into R 4.1.0. Gene expression data were analyzed using Seurat software 4.0.3. After singlets were identified, abnormal cells were excluded from downstream analysis by the median absolute deviation (MAD) method. Cells with a median mitochondria reads percentage greater than 3MAD, median expressed genes less than 3MAD, or median UMI count less than 3MAD were considered abnormal. To avoid the influence of confounding factors such as cell cycle stage, sequencing depth and percent mitochondrial, these confounding factors were removed from the analysis by Seurat.

[0096] 3. Dimensionality Reduction To obtain a two-dimensional projection of the population dynamics, we processed the top 2000 highly variable genes in the normalized gene barcode matrix by Seurat's principal component analysis (PCA), and performed dimensionality reduction on the matrix to obtain low-dimensional spatial information. We then performed uniform manifold approximation and projection (UMAP) to process the top 30 principal components (PCs), achieving cell visualization in two-dimensional space. The steps included the following: Normalize the data using the NormalizeData function (normalization.method = "LogNormalize") Select the top 2000 genes, ranked based on variance, as highly variable genes (HVG) using the FindVariableFeature function (selection.method="vst", nfeatures=2000); 2000 highly variable genes were normalized using the ScaleData function to remove noise due to factors such as the cell cycle. Reduce the dimensionality of the data using the RunPCA function (features = VariableFeatures (object = adsc)). Constructing a neighborhood graph using the shared nearest neighbor similarity algorithm (SNN) of the FindNeighbors function; Use the FindClusters function to adjust the parameters of the SNN model results (resolution = 0.1 ~ 1) to determine the number of cell subpopulations; Perform visualization and dimensionality reduction analysis using the RunUMAP function. Figure 3A shows the clustering results of cell subpopulations of D1M1-P5 and D1M2-P5, which included six different populations (0-5), and there were obvious differences in the occupancy of each population in D1M1-P5 and D1M2-P5. Based on GO and KEGG, risk genes of mesenchymal stromal cells were excavated, and as shown in Figure 3B and Figure 3C, there were also differences in the expression of each subpopulation for risk genes. This indicates that mesenchymal stromal cells generate heterogeneity in different media, and the gene expression profiles of D1M1-P5 and D1M2-P5 were completely different.

[0097] 4. Functional Clustering Analysis of Cell Subpopulations To convert the sparse gene expression matrix into a pathway score matrix, all genes in the gene expression matrix were scored based on classical pathways. Then, the pathway score matrix was subjected to dimensionality reduction and visualization to obtain the functional clustering results of cell subpopulations. A schematic diagram of the mechanism is shown in Figure 4. The steps are briefly described as follows: Pathway enrichment analysis was performed on the single-cell gene expression data, and the canonical pathway scores in each mesenchymal stromal cell were calculated using the ssGSEA, AUCell, and Seurat scoring functions to obtain a pathway score matrix. Dimensionality reduction and visualization were then performed based on the pathway score matrix as described above. As shown in Figure 5A, Figure 5B and Figure 5C, the clustering results by the three different scoring functions were the same. The cell subpopulations of D1M1-P5 (i.e., A2105C2P5) and D1M2-P5 (i.e., A2105C3P5) were distinguished and separated from each other. D1M1-P5 were both quality risk mesenchymal stromal cells, and D1M2-P5 were both non-quality risk mesenchymal stromal cells, indicating that mesenchymal stromal cells underwent significant functional changes after being cultured in different media, which is consistent with the results of the animal experiments in Example 2. The functional clustering process developed here can provide a valuable tool for identifying specific functional subpopulations based on their transcriptome profiles. By the cell culture method as shown in FIG. 6, the multipotent mesenchymal stromal cells derived from donor 1 were subcultured from the first to the third passage using M1 or M2 medium, and then the medium was replaced and the cells were subcultured up to the fifth passage. The quality of the mesenchymal stromal cells at the third and fifth passages was determined by functional clustering analysis. As a result, as shown in Figures 7A, 7B, and 7C, mesenchymal stromal cells cultured in M1 medium and mesenchymal stromal cells cultured in M2 medium were different cell subpopulations. All mesenchymal stromal cells cultured in M1 medium were quality risk mesenchymal stromal cells, and all mesenchymal stromal cells cultured in M2 medium were non-quality risk mesenchymal stromal cells. Heterogeneity occurs when mesenchymal stromal cells grow under different culture conditions. According to the animal experiment results in Figures 8A and 8B, D1M1-P3 and D1M2 / M1-P5 induced pulmonary embolism in mice, but D1M2-P3 and D1M1 / M2-P5 did not induce pulmonary embolism in mice, indicating the accuracy of the functional clustering results.

[0098] Example 6 Identification of Subpopulations In this example, a mesenchymal stromal cell quality prediction model was constructed based on decision tree, random forest, or support vector machine (SVM). The dataset is listed in Table 11. A schematic diagram of the mechanism is shown in Figure 10. D1M1-P5 and D1M2-P5 respectively indicate multipotent mesenchymal stromal cells obtained by subculturing primary multipotent mesenchymal stromal cells from donor 1 and cultured in M1 or M2 medium up to the fifth passage. D1M1-P3 and D1M2-P3 respectively indicate multipotent mesenchymal stromal cells obtained by subculturing primary multipotent mesenchymal stromal cells from donor 1 and cultured in M1 or M2 medium up to the third passage. D2M1-P5 and D2M2-P5 represent pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells derived from donor 2 and cultured in M1 or M2 medium up to passage 5, respectively. D2M3 / M2-P5 represent pluripotent mesenchymal stromal cells obtained by subculturing primary pluripotent mesenchymal stromal cells derived from donor 2 and cultured in M3 medium (αMEM+5% Helios UltraGRO-Advanced) up to passage 3 and then in M2 medium up to passage 5.

[0099] [Table 11]

[0100] The steps were as follows: 1. Initial hyperparameters In the random forest models, the estimator (n_estimator) was 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000, and the maximum tree depth (max_depth) was 3, 5, or 7. In the support vector machine models, the regularization parameter C was 0.2, 0.6, 0.8, 1.0, 1.2, 1.6, 2.0, 2.2, 2.6, and 3.0, and the kernel parameter (kemel) was linear, "poly", "rbf", or "sigmoid".

[0101] 2. Feature Selection A machine learning method combining recursive feature reduction and cross-validation was used to rank each gene in the training set for its importance in distinguishing quality risk from non-quality risk mesenchymal stromal cells. The most significant genes were added one by one, and the accuracy rate of 10-fold cross-validation was calculated to determine the matching feature genes and the number of feature genes. As shown in FIG. 11, when the most important gene was selected as the feature gene, the accuracy rates of the models with different normalization parameters C in the 10-fold cross-validation in the training set all exceeded 94%, and when the most important 13 genes (TAGLN, EFEMP1, TPM1, CLU, PTX3, IER3, IGFBP7, MFAP5, IL6, LUM, SERPINE2, CRIM1 and RHOB) were selected as the feature genes, the accuracy rates of the models with different normalization parameters C in the 10-fold cross-validation in the training set all reached 100%.

[0102] 3. Model derivation A linear SVM model was developed using 13 feature genes, and the model coefficient matrix (model weight matrix) was optimized by cross-validation to indicate the importance score of the feature genes. The models were trained with test set 1, test set 2, test set 3 and test set 4, respectively, and the regularization parameter C was adjusted according to the prediction accuracy. Based on the test results shown in Table 12, the linear SVM model with the best representation in all test sets (C=0.0005) was selected as the mesenchymal stromal cell quality prediction model.

[0103] [Table 12]

[0104] As shown in Table 13, the predicted results of the determined mesenchymal stromal cell quality prediction model (support vector machine model, model complexity parameter C = 0.0005) for different types of mesenchymal stromal cells have good measurement accuracy, precision, recall and F1 score in four test sets. The determined 13 feature genes and their corresponding weight coefficients are shown in Table 14.

[0105] [Table 13] [Table 14]

[0106] 4. Mesenchymal Stromal Cell Quality Score at Single-cell Level Based on the expression levels of the identified 13 characteristic genes and the weighting coefficients of each characteristic gene determined by the mesenchymal stromal cell quality prediction model, the quality score of mesenchymal stromal cells at the single cell level was calculated using the following function to quantify the quality risk of a single mesenchymal stromal cell.

[0107]

number

[0108] Wherein, Gi is the expression level of the i-th feature gene in a single mesenchymal stromal cell, Wi is the weight coefficient of the i-th feature gene, and n is the quantity of the feature gene. A positive value of Wi indicates that an increase in the expression of the feature gene promotes the quality risk of mesenchymal stromal cells, and a negative value of Wi indicates that an increase in the expression of the feature gene suppresses the quality risk of mesenchymal stromal cells.

[0109] The quality scores of mesenchymal stromal cells and the risk score thresholds in the four test sets were evaluated using receiver operating characteristic (ROC) curves and areas under the curve (AUC).

[0110] FIG. 12 shows the ROC curves and corresponding AUCs of test set 1, test set 2, test set 3 and test set 4. The highest value of the ROC curve (the one with the highest sensitivity and specificity) was taken as the threshold value for determining whether the mesenchymal stromal cells of the test set were quality risk mesenchymal stromal cells or non-quality risk mesenchymal stromal cells. According to the ROC curve, the quality score thresholds of the four test sets were defined as 3.961 (AUC=1), 3.961 (AUC=1), 5.312 (AUC=0.986) and 6.680 (AUC=0.993), respectively. Specific results are shown in FIG. 12A, FIG. 12B, FIG. 12C and FIG. 12D.

[0111] Example 7 Mesenchymal stromal cell quality evaluation system In this embodiment, the mesenchymal stromal cell quality evaluation system includes an evaluation subsystem 10 . As shown in FIG. 13A, the evaluation subsystem 10 includes: a quality scoring module 110 for calculating a quality score of the mesenchymal stromal cells based on the expression levels of the characteristic genes related to the quality of the mesenchymal stromal cells and the weighting coefficients of the characteristic genes; and a quality assessment module 120 for assessing the quality of the mesenchymal stromal cells based on the quality score of the mesenchymal stromal cells. As shown in FIG. 13B, the quality scoring module 110: a feature gene expression level acquisition unit 1110 for acquiring the expression level of a feature gene related to the quality of a mesenchymal stromal cell; and a calculation unit 1120 for calculating a quality score of the mesenchymal stromal cells based on the expression levels of the feature genes and the weight coefficients of the feature genes. The calculation function for the quality score of the mesenchymal stromal cells is as follows:

[0112]

number

[0113] In the formula, Gi is the expression level of the i-th feature gene, Wi is the weight coefficient of the i-th feature gene, and n is the quantity of the feature gene. As shown in FIG. 13C, the quality assessment module 120 A mesenchymal stromal cell quality risk threshold determination unit 1210 for analyzing the quality score of mesenchymal stromal cells in a dataset by a receiver operating characteristic curve and an area under the curve, the numerical value of the highest point of the receiver operating characteristic curve being a mesenchymal stromal cell quality risk threshold, the dataset including single cell gene expression data of mesenchymal stromal cells having a known specific quality attribute; a comparison and judgment unit 1220 for comparing the quality score of the mesenchymal stromal cell with a quality risk threshold; If the quality score of the mesenchymal stromal cells is greater than or equal to the quality risk threshold of the mesenchymal stromal cells, the mesenchymal stromal cells are quality risk mesenchymal stromal cells, and if the quality score of the mesenchymal stromal cells is less than the quality risk threshold of the mesenchymal stromal cells, the mesenchymal stromal cells are non-quality risk mesenchymal stromal cells. The evaluation subsystem 10 includes a result output module for outputting a report of the evaluation results of the mesenchymal stromal cell quality. The mesenchymal stromal cell quality assessment system further includes an optimization subsystem 20 .

[0114] As shown in FIG. 13D, the optimization subsystem 20: a subpopulation clustering module 210 for obtaining single cell gene expression data and specific quality attributes of mesenchymal stromal cells; and a subpopulation identification module 220 for determining and / or optimizing mesenchymal stromal cell quality prediction models, feature genes associated with mesenchymal stromal cell quality and feature gene weighting coefficients based on single-cell gene expression data and specific quality attributes of mesenchymal stromal cells.

[0115] As shown in FIG. 13E, the subpopulation clustering module 210: a single-cell gene expression data acquisition unit 2110 for preprocessing the single-cell RNA sequencing data and obtaining single-cell gene expression data of mesenchymal stromal cells; A pathway score matrix acquisition unit 2120 for performing pathway enrichment analysis on the single-cell gene expression data of the mesenchymal stromal cells and calculating the pathway score of each mesenchymal stromal cell; and a specific quality attribute determination unit 2130 for performing dimensionality reduction and clustering on the pathway score matrix to obtain a clustering result as a specific quality attribute of mesenchymal stromal cells.

[0116] As shown in FIG. 13F, the subpopulation identification module 220: A dataset creation unit 2210 for forming single-cell gene expression data of mesenchymal stromal cells with specific quality attribute labels into a dataset; a dataset splitting unit 2220 for splitting the dataset into a training set and a test set; A model training unit 2230 for training a supervised machine learning model using the training set, adjusting parameters of the supervised machine learning model using cross-validation and a test set, and determining and / or optimizing a mesenchymal stromal cell quality prediction model; and a feature gene output unit 2240 for outputting feature genes and weighting coefficients related to the mesenchymal stromal cell quality according to the mesenchymal stromal cell quality prediction model.

[0117] Example 8 Quality assessment of mesenchymal stromal cell samples using the system Based on the identified 13 characteristic genes and weighting coefficients (Table 14) determined by the mesenchymal stromal cell quality prediction model, the expression levels of the characteristic genes at the single cell level of D1M1 / M2-P5 and D1M2 / M1-P5 were examined using subsystem 10 of the mesenchymal stromal cell quality evaluation system. To evaluate the mesenchymal stromal cell quality, the quality scores of D1M1 / M2-P5 and D1M2 / M1-P5 were calculated by a formula. The quality score threshold was 3.961.

[0118] As a result, as shown in Figure 14, in D1M2 / M1-P5, 99.90% of mesenchymal stromal cells were quality risk mesenchymal stromal cells and 0.10% of mesenchymal stromal cells were non-quality risk mesenchymal stromal cells, whereas in D1M1 / M2-P5, 0.24% of mesenchymal stromal cells were quality risk mesenchymal stromal cells and 99.76% of mesenchymal stromal cells were non-quality risk mesenchymal stromal cells. The prediction results are consistent with the functional clustering results of cell subpopulations in Figures 7A, 7B, and 7C, and the results of animal experiments shown in Figures 8A and 8B. This indicates that the quality prediction model can accurately predict the quality risk of mesenchymal stromal cells.

[0119] Example 9: Analysis service using the system When a user uploads single-cell RNA sequencing data of mesenchymal stromal cells to the analysis website, the quality scoring module 110 of the evaluation subsystem 10 in the mesenchymal stromal cell quality evaluation system obtains the expression levels of feature genes related to the mesenchymal stromal cell quality of the mesenchymal stromal cells, and calculates a quality score of the mesenchymal stromal cells based on the expression levels of the feature genes and the weighting coefficients of the feature genes.

[0120] The calculation function of the quality score of the mesenchymal stromal cells is as follows:

[0121]

number

[0122] The quality assessment module 120 of the assessment subsystem 10 compares the mesenchymal stromal cell quality score with a mesenchymal stromal cell quality risk threshold. if the quality score of the mesenchymal stromal cells is equal to or greater than the threshold value of the mesenchymal stromal cell quality risk, the mesenchymal stromal cells are quality risk mesenchymal stromal cells; If the quality score of the mesenchymal stromal cells is < the mesenchymal stromal cell quality risk threshold, the mesenchymal stromal cells are non-quality risk mesenchymal stromal cells. The result output module of the evaluation subsystem 10 outputs an evaluation report of the mesenchymal stromal cell quality.

[0123] When the administrator upgrades the analysis website, the subpopulation clustering module 210 of the optimization subsystem 20 in the mesenchymal stromal cell quality evaluation system preprocesses the single-cell RNA sequencing data to obtain single-cell gene expression data, performs pathway enrichment analysis on the single-cell gene expression data to calculate pathway scores in each mesenchymal stromal cell, and obtains a pathway score matrix, performs dimensionality reduction and clustering on the pathway score matrix, and obtains the clustering results as specific quality attributes of mesenchymal stromal cells.

[0124] The subpopulation identification module 220 integrates single-cell gene expression data of mesenchymal stromal cells with specific quality attributes into the original dataset to form a new dataset divided into a training set and a test set. The training set and the test set are used to optimize the mesenchymal stromal cell quality prediction model. The feature genes and weighting coefficients related to the mesenchymal stromal cell quality are output. The quality scoring module 110 in the evaluation subsystem 10 obtains the expression levels of feature genes associated with mesenchymal stromal cell quality, and calculates a quality score of the mesenchymal stromal cells based on the expression levels of the feature genes and the weighting coefficients of the feature genes. The calculation function of the quality score of the mesenchymal stromal cells is as follows:

[0125]

number

[0126] The quality assessment module 120 of the assessment subsystem 10 compares the quality score of mesenchymal stromal cells to a quality risk threshold, wherein the dataset includes single cell gene expression data of mesenchymal stromal cells having known particular quality attributes. if the quality score of the mesenchymal stromal cells is equal to or greater than the threshold value of the mesenchymal stromal cell quality risk, the mesenchymal stromal cells are quality risk mesenchymal stromal cells; Mesenchymal stromal cell quality score <間葉系間質細胞品質リスクの閾値であると、間葉系間質細胞が非品質リスク間葉系間質細胞である。The result output module of the evaluation subsystem 10 outputs an evaluation report of the mesenchymal stromal cell quality. In the present invention, the specific methods of the present invention are described in the above examples, but the present invention is not limited to these specific methods, that is, it does not mean that the present invention must be carried out by relying on the above specific methods. Any improvements to the present invention, equivalent replacement of each raw material of the product of the present invention, addition of auxiliary ingredients, selection of specific methods, etc. are all within the protection scope and disclosure scope of the present invention.

Claims

1. a quality scoring module for calculating a quality score of the stem cell based on the expression levels of the characteristic genes related to the stem cell quality and the weight coefficients of the characteristic genes; and a quality evaluation module for evaluating the quality of stem cells based on the quality score of the stem cells.

2. The quality scoring module: (1) a characteristic gene expression level acquisition unit for acquiring an expression level of a characteristic gene related to stem cell quality; (2) a calculation unit for calculating a quality score of a stem cell according to the expression levels of the characteristic genes and the weight coefficients of the characteristic genes; The stem cell quality evaluation system of claim 1 , wherein the calculation function for the stem cell quality score is as follows: [0010] (wherein, Gi is the expression level of the i-th feature gene, Wi is the weight coefficient of the i-th feature gene, and n is the quantity of the feature gene.)

3. The quality assessment module: (1) A stem cell quality risk threshold judgment unit for analyzing the quality score of a data set of stem cells by a receiver operating characteristic curve and an area under the curve, the highest value of the receiver operating characteristic curve being the stem cell quality risk threshold, the data set including single cell gene expression data of stem cells having a known specific quality attribute; (2) a comparison judgment unit for comparing the stem cell quality score and the stem cell quality risk threshold; The stem cell quality evaluation system of claim 1 or 2, wherein if the stem cell quality score is greater than or equal to the stem cell quality risk threshold, the stem cell is a quality risk stem cell, and if the stem cell quality score is less than the stem cell quality risk threshold, the stem cell is a non-quality risk stem cell.

4. The stem cell quality evaluation system according to any one of claims 1 to 3, further comprising a result output module for outputting a result report of stem cell quality.

5. The stem cell quality evaluation system according to any one of claims 1 to 4, wherein the stem cells include any one or a combination of at least two of adult stem cells, embryonic stem cells, induced pluripotent stem cells, or stem cells transformed from mature somatic cells, and their derived cells.

6. The stem cell quality evaluation system according to any one of claims 1 to 5, wherein the stem cells comprise any one or a combination of at least two of mesenchymal stem cells, mesenchymal stromal cells, multipotent stromal cells, multipotent mesenchymal stromal cells, or medicinal signaling cells.

7. The stem cell quality evaluation system according to any one of claims 1 to 6, wherein the stem cells comprise any one or a combination of at least two of the following: adipose-derived stem cells, umbilical cord mesenchymal stem cells, placenta-derived stem cells, bone marrow mesenchymal stem cells, dental marrow mesenchymal stem cells, menstrual blood-derived stem cells, amniotic epithelial stem cells, and bronchial basal cells.

8. a subpopulation clustering module for obtaining single cell gene expression data and specific quality attributes of stem cells; and a subpopulation identification module for determining and / or optimizing a stem cell quality prediction model, feature genes associated with stem cell quality, and weighting coefficients of the feature genes based on single-cell gene expression data and specific quality attributes of the stem cells.

9. the subpopulation clustering module comprising: (1) a single-cell gene expression data acquisition unit for preprocessing single-cell RNA sequencing data to obtain single-cell gene expression data of stem cells; (2) a pathway score matrix acquisition unit for performing pathway enrichment analysis on the single-cell gene expression data of stem cells and calculating the pathway score of each stem cell; (3) a specific quality attribute determination unit for performing dimensionality reduction and clustering on the pathway score matrix and obtaining the clustering result as a specific quality attribute of stem cells.

10. the subpopulation identification module comprising: (1) a dataset creation unit for forming single-cell gene expression data of stem cells having specific quality attributes into a dataset; (2) a dataset splitting unit for splitting the dataset into a training set and a test set; (3) a model training unit for training a supervised machine learning model by the training set, adjusting parameters of the supervised machine learning model by cross-validation and a test set, and determining and / or optimizing a stem cell quality prediction model; (4) a feature gene output unit for outputting feature genes and weighting coefficients related to stem cell quality according to the stem cell quality prediction model.

11. 11. The optimization subsystem of any one of claims 8 to 10, wherein the supervised machine learning model comprises any one of a perceptron model, a K-nearest neighbor model, a naive Bayes model, a decision tree model, a logistic regression, a support vector machine, a random forest, a boosting model, an EM algorithm, or a conditional random field.

12. obtaining single cell gene expression data of stem cells and specific quality attributes to form a dataset divided into a training set and a test set; A method for constructing a stem cell quality prediction model, comprising: training a supervised machine learning model using a training set; adjusting parameters of the supervised machine learning model through cross-validation and testing using a test set; and determining the stem cell quality prediction model.

13. Obtaining single cell gene expression data and specific quality attributes of the stem cells includes: Obtaining single-cell gene expression data of stem cells by performing single-cell RNA sequencing on the stem cells; performing pathway enrichment analysis on single-cell gene expression data of stem cells and calculating a pathway enrichment score for each stem cell to obtain a pathway score matrix; The method for constructing a stem cell quality prediction model described in claim 12, comprising performing bioinformatics analysis on the pathway score matrix to obtain stem cell clustering results as specific quality attributes of stem cells.

14. The bioinformatics analysis of the stem cell pathway score matrix includes: A method for constructing a stem cell quality prediction model as described in claim 12 or 13, comprising performing dimensionality reduction and clustering processing on a pathway score matrix.

Citation Information

Patent Citations

  • Stem cell quality evaluation system and application method

    CN113061638A

  • Method for evaluating quality of pluripotent stem cells

    CN113658636A

  • Method for evaluating cell aging degree based on transcriptome data and machine learning strategy

    CN113838531A

  • Molecular diagnostic tests for cancer

    JP2013537045A

  • Mesenchymal stromal cell quality evaluation method

    JP2024543933A

Cited By

  • Mesenchymal stromal cell quality evaluation method

    JP2024543933A

  • Mesenchymal stromal cell quality evaluation method

    JP7795630B2

  • Information processing device, information processing method, and program

    WO2026182124A1